English
简体中文
Total: £ 56.28
Published Date: 2025-11-11 | Pages: 117 | Tables: 121 | Medical Care
The global GLP-1 Peptide Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Glucagon-likepeptide-1 (GLP-1) is a hormone secreted by intestinal L cells. Its receptor (GLP-1R) is widely distributed in the central nervous system, cardiovascular system, muscles, and gastrointestinal tract. multiple organs and tissues. GLP-1 has glucose concentration-dependent hypoglycemic effects, and its receptor agonist (GLP-1RA) can simulate the physiological effects of GLP-1 and is an important drug for the treatment of diabetes and obesity. In addition, GLP-1RA also has protective effects on the cardiovascular system, kidneys, central nervous system, etc.
GLP-1 peptide drugs are often used to treat patients with type 2 diabetes. They can control blood sugar while also bringing weight loss and reducing cardiovascular risk.
From a downstream perspective, Type 2 Diabetes accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
GLP-1 Peptide Drugs leading manufacturers including AstraZeneca, Novo Nordisk, Sanofi, GSK, Eli Lilly, Benemae Pharmaceutical, Hansoh Pharmaceutical, etc., dominate supply; the top five capture approximately % of global revenue, with AstraZeneca leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global GLP-1 Peptide Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
AstraZeneca
Novo Nordisk
Sanofi
GSK
Eli Lilly
Benemae Pharmaceutical
Hansoh Pharmaceutical
Segment by Type
Injection
Oral
Segment by Application
Type 2 Diabetes
Obesity
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the GLP-1 Peptide Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to GLP-1 Peptide Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global GLP-1 Peptide Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Injection
1.2.3 Oral
1.3 Market Segmentation by Application
1.3.1 Global GLP-1 Peptide Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Type 2 Diabetes
1.3.3 Obesity
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global GLP-1 Peptide Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global GLP-1 Peptide Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global GLP-1 Peptide Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global GLP-1 Peptide Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Injection Market Size by Players
3.3.2 Oral Market Size by Players
3.4 Global GLP-1 Peptide Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global GLP-1 Peptide Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global GLP-1 Peptide Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America GLP-1 Peptide Drugs Market Size by Type (2020-2031)
6.4 North America GLP-1 Peptide Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America GLP-1 Peptide Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe GLP-1 Peptide Drugs Market Size by Type (2020-2031)
7.4 Europe GLP-1 Peptide Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe GLP-1 Peptide Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific GLP-1 Peptide Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific GLP-1 Peptide Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific GLP-1 Peptide Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America GLP-1 Peptide Drugs Market Size by Type (2020-2031)
9.4 Central and South America GLP-1 Peptide Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America GLP-1 Peptide Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa GLP-1 Peptide Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa GLP-1 Peptide Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa GLP-1 Peptide Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca GLP-1 Peptide Drugs Product Features and Attributes
11.1.4 AstraZeneca GLP-1 Peptide Drugs Revenue and Gross Margin (2020-2025)
11.1.5 AstraZeneca GLP-1 Peptide Drugs Revenue by Product in 2024
11.1.6 AstraZeneca GLP-1 Peptide Drugs Revenue by Application in 2024
11.1.7 AstraZeneca GLP-1 Peptide Drugs Revenue by Geographic Area in 2024
11.1.8 AstraZeneca GLP-1 Peptide Drugs SWOT Analysis
11.1.9 AstraZeneca Recent Developments
11.2 Novo Nordisk
11.2.1 Novo Nordisk Corporation Information
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk GLP-1 Peptide Drugs Product Features and Attributes
11.2.4 Novo Nordisk GLP-1 Peptide Drugs Revenue and Gross Margin (2020-2025)
11.2.5 Novo Nordisk GLP-1 Peptide Drugs Revenue by Product in 2024
11.2.6 Novo Nordisk GLP-1 Peptide Drugs Revenue by Application in 2024
11.2.7 Novo Nordisk GLP-1 Peptide Drugs Revenue by Geographic Area in 2024
11.2.8 Novo Nordisk GLP-1 Peptide Drugs SWOT Analysis
11.2.9 Novo Nordisk Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview
11.3.3 Sanofi GLP-1 Peptide Drugs Product Features and Attributes
11.3.4 Sanofi GLP-1 Peptide Drugs Revenue and Gross Margin (2020-2025)
11.3.5 Sanofi GLP-1 Peptide Drugs Revenue by Product in 2024
11.3.6 Sanofi GLP-1 Peptide Drugs Revenue by Application in 2024
11.3.7 Sanofi GLP-1 Peptide Drugs Revenue by Geographic Area in 2024
11.3.8 Sanofi GLP-1 Peptide Drugs SWOT Analysis
11.3.9 Sanofi Recent Developments
11.4 GSK
11.4.1 GSK Corporation Information
11.4.2 GSK Business Overview
11.4.3 GSK GLP-1 Peptide Drugs Product Features and Attributes
11.4.4 GSK GLP-1 Peptide Drugs Revenue and Gross Margin (2020-2025)
11.4.5 GSK GLP-1 Peptide Drugs Revenue by Product in 2024
11.4.6 GSK GLP-1 Peptide Drugs Revenue by Application in 2024
11.4.7 GSK GLP-1 Peptide Drugs Revenue by Geographic Area in 2024
11.4.8 GSK GLP-1 Peptide Drugs SWOT Analysis
11.4.9 GSK Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Corporation Information
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly GLP-1 Peptide Drugs Product Features and Attributes
11.5.4 Eli Lilly GLP-1 Peptide Drugs Revenue and Gross Margin (2020-2025)
11.5.5 Eli Lilly GLP-1 Peptide Drugs Revenue by Product in 2024
11.5.6 Eli Lilly GLP-1 Peptide Drugs Revenue by Application in 2024
11.5.7 Eli Lilly GLP-1 Peptide Drugs Revenue by Geographic Area in 2024
11.5.8 Eli Lilly GLP-1 Peptide Drugs SWOT Analysis
11.5.9 Eli Lilly Recent Developments
11.6 Benemae Pharmaceutical
11.6.1 Benemae Pharmaceutical Corporation Information
11.6.2 Benemae Pharmaceutical Business Overview
11.6.3 Benemae Pharmaceutical GLP-1 Peptide Drugs Product Features and Attributes
11.6.4 Benemae Pharmaceutical GLP-1 Peptide Drugs Revenue and Gross Margin (2020-2025)
11.6.5 Benemae Pharmaceutical Recent Developments
11.7 Hansoh Pharmaceutical
11.7.1 Hansoh Pharmaceutical Corporation Information
11.7.2 Hansoh Pharmaceutical Business Overview
11.7.3 Hansoh Pharmaceutical GLP-1 Peptide Drugs Product Features and Attributes
11.7.4 Hansoh Pharmaceutical GLP-1 Peptide Drugs Revenue and Gross Margin (2020-2025)
11.7.5 Hansoh Pharmaceutical Recent Developments
12 GLP-1 Peptide DrugsIndustry Chain Analysis
12.1 GLP-1 Peptide Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 GLP-1 Peptide Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global GLP-1 Peptide Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global GLP-1 Peptide Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global GLP-1 Peptide Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global GLP-1 Peptide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global GLP-1 Peptide Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global GLP-1 Peptide Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global GLP-1 Peptide Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global GLP-1 Peptide Drugs Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global GLP-1 Peptide Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Peptide Drugs as of 2024)
Table 11. Global GLP-1 Peptide Drugs Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global GLP-1 Peptide Drugs Companies Headquarters
Table 13. Global GLP-1 Peptide Drugs Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global GLP-1 Peptide Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global GLP-1 Peptide Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global GLP-1 Peptide Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global GLP-1 Peptide Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 21. GLP-1 Peptide Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America GLP-1 Peptide Drugs Growth Accelerators and Market Barriers
Table 25. North America GLP-1 Peptide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe GLP-1 Peptide Drugs Growth Accelerators and Market Barriers
Table 27. Europe GLP-1 Peptide Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific GLP-1 Peptide Drugs Growth Accelerators and Market Barriers
Table 29. Asia-Pacific GLP-1 Peptide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America GLP-1 Peptide Drugs Investment Opportunities and Key Challenges
Table 31. Central and South America GLP-1 Peptide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa GLP-1 Peptide Drugs Investment Opportunities and Key Challenges
Table 33. Middle East and Africa GLP-1 Peptide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. AstraZeneca Corporation Information
Table 35. AstraZeneca Description and Major Businesses
Table 36. AstraZeneca Product Features and Attributes
Table 37. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. AstraZeneca Revenue Proportion by Product in 2024
Table 39. AstraZeneca Revenue Proportion by Application in 2024
Table 40. AstraZeneca Revenue Proportion by Geographic Area in 2024
Table 41. AstraZeneca GLP-1 Peptide Drugs SWOT Analysis
Table 42. AstraZeneca Recent Developments
Table 43. Novo Nordisk Corporation Information
Table 44. Novo Nordisk Description and Major Businesses
Table 45. Novo Nordisk Product Features and Attributes
Table 46. Novo Nordisk Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Novo Nordisk Revenue Proportion by Product in 2024
Table 48. Novo Nordisk Revenue Proportion by Application in 2024
Table 49. Novo Nordisk Revenue Proportion by Geographic Area in 2024
Table 50. Novo Nordisk GLP-1 Peptide Drugs SWOT Analysis
Table 51. Novo Nordisk Recent Developments
Table 52. Sanofi Corporation Information
Table 53. Sanofi Description and Major Businesses
Table 54. Sanofi Product Features and Attributes
Table 55. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Sanofi Revenue Proportion by Product in 2024
Table 57. Sanofi Revenue Proportion by Application in 2024
Table 58. Sanofi Revenue Proportion by Geographic Area in 2024
Table 59. Sanofi GLP-1 Peptide Drugs SWOT Analysis
Table 60. Sanofi Recent Developments
Table 61. GSK Corporation Information
Table 62. GSK Description and Major Businesses
Table 63. GSK Product Features and Attributes
Table 64. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. GSK Revenue Proportion by Product in 2024
Table 66. GSK Revenue Proportion by Application in 2024
Table 67. GSK Revenue Proportion by Geographic Area in 2024
Table 68. GSK GLP-1 Peptide Drugs SWOT Analysis
Table 69. GSK Recent Developments
Table 70. Eli Lilly Corporation Information
Table 71. Eli Lilly Description and Major Businesses
Table 72. Eli Lilly Product Features and Attributes
Table 73. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Eli Lilly Revenue Proportion by Product in 2024
Table 75. Eli Lilly Revenue Proportion by Application in 2024
Table 76. Eli Lilly Revenue Proportion by Geographic Area in 2024
Table 77. Eli Lilly GLP-1 Peptide Drugs SWOT Analysis
Table 78. Eli Lilly Recent Developments
Table 79. Benemae Pharmaceutical Corporation Information
Table 80. Benemae Pharmaceutical Description and Major Businesses
Table 81. Benemae Pharmaceutical Product Features and Attributes
Table 82. Benemae Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Benemae Pharmaceutical Recent Developments
Table 84. Hansoh Pharmaceutical Corporation Information
Table 85. Hansoh Pharmaceutical Description and Major Businesses
Table 86. Hansoh Pharmaceutical Product Features and Attributes
Table 87. Hansoh Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Hansoh Pharmaceutical Recent Developments
Table 89. Raw Materials Key Suppliers
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. GLP-1 Peptide Drugs Product Picture
Figure 2. Global GLP-1 Peptide Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Injection Product Picture
Figure 4. Oral Product Picture
Figure 5. Global GLP-1 Peptide Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Type 2 Diabetes
Figure 7. Obesity
Figure 8. Others
Figure 9. GLP-1 Peptide Drugs Report Years Considered
Figure 10. Global GLP-1 Peptide Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 12. Global GLP-1 Peptide Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global GLP-1 Peptide Drugs Revenue Market Share by Region (2020-2031)
Figure 14. Global GLP-1 Peptide Drugs Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Injection Revenue Market Share by Player in 2024
Figure 17. Oral Revenue Market Share by Player in 2024
Figure 18. Global GLP-1 Peptide Drugs Revenue Market Share by Type (2020-2031)
Figure 19. Global GLP-1 Peptide Drugs Revenue Market Share by Application (2020-2031)
Figure 20. North America GLP-1 Peptide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players GLP-1 Peptide Drugs Revenue (US$ Million) in 2024
Figure 22. North America GLP-1 Peptide Drugs Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America GLP-1 Peptide Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 24. US GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 25. Canada GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 27. Europe GLP-1 Peptide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players GLP-1 Peptide Drugs Revenue (US$ Million) in 2024
Figure 29. Europe GLP-1 Peptide Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe GLP-1 Peptide Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 32. France GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 34. Italy GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 35. Russia GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific GLP-1 Peptide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players GLP-1 Peptide Drugs Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific GLP-1 Peptide Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific GLP-1 Peptide Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 41. Japan GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 43. Australia GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. India GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore GLP-1 Peptide Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America GLP-1 Peptide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players GLP-1 Peptide Drugs Revenue (US$ Million) in 2024
Figure 52. Central and South America GLP-1 Peptide Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America GLP-1 Peptide Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil GLP-1 Peptide Drugs Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina GLP-1 Peptide Drugs Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa GLP-1 Peptide Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players GLP-1 Peptide Drugs Revenue (US$ Million) in 2024
Figure 58. South America GLP-1 Peptide Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa GLP-1 Peptide Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries GLP-1 Peptide Drugs Revenue (2020-2025) & (US$ Million)
Figure 61. Israel GLP-1 Peptide Drugs Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt GLP-1 Peptide Drugs Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa GLP-1 Peptide Drugs Revenue (2020-2025) & (US$ Million)
Figure 64. GLP-1 Peptide Drugs Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
